{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"The RP2D was determined by a traditional 3+3 dose-escalation design of single-agent INCB001158 in participants with advanced/metastatic solid tumors at doses of 50, 75, 100, or 150 mg.","groups":[{"description":"Monotherapy Part 1a: INCB001158 was administered orally in participants with advanced/metastatic solid tumors. Sequential dose escalation of single-agent INCB001158 took place in participants with advanced/metastatic solid tumors.","id":"OG000","title":"INCB001158 as Monotherapy at 50, 75, 100 and 150 mg BID"}],"paramType":"NUMBER","populationDescription":"Safety Population","reportingStatus":"POSTED","timeFrame":"12 weeks","title":"Recommended Phase 2 Dose (RP2D) of INCB001158","type":"SECONDARY","unitOfMeasure":"milligrams"}